Skip to content
Company Analysis

Nephros, Inc. NEPH

A comprehensive view of key metrics, scores, and financial health for Nephros, Inc.

Overview of Nephros, Inc.

NEPH NCM
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Micro Cap
Nephros, Inc. (NEPH), is a Micro Cap company, in the Medical Instruments & Supplies industry, last closed at $4.36, about 39.4% overvalued vs fair value, +2.3% 1Y return, ranked 684/1145 in sector.
Metrics P/E 44.8× Rev Growth 32.7% ROE 12.7% Gross Margin 61.9%
USD 4.36
7.39%
(Delayed)
• Vol 90d: 86.6%
52-Week Range
Market Cap
$35.94M
Enterprise Value
$32.11M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Fair
Completeness: 100%
Confidence: 61%
Updated: Sep 12
Top Beats

Quick Facts

Website https://www.nephros.com
HQ South Orange, NJ
Employees 31
Fiscal year Dec 31

Next Events

Earnings Nov 5 Estimated

Fair Value Snapshot

Bear Base Bull
$2
$3
$3
Current: $4.36 -39% vs base

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$18.8M
32.7%%
Gross Profit
$11.6M
33.3%%
Operating Income (GAAP)
$1.1M
19000%%
EBITDA
$1.3M
493.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
61.9%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
3
Active Leaks
2/3
Improving
1
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Nephros, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
65
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Superior Capital Returns Capital return quality is top-tier (score 0.87). High ROIC indicates the business is reinvesting at attractive rates.
  • Comfortable Interest Coverage Interest coverage quality is strong vs peers (score 1.00). Debt servicing capacity supports continued M&A optionality.

Key risks

  • Gross Margin Volatility Gross margin stability is poor (score 0.31). Margin volatility undermines the consumable moat thesis.
  • Declining Capital Returns ROIC durability is weak (score 0.23). Volatility or decline in returns is a leading moat erosion signal.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
56
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing NEPH's balance between Growth (35.4%), Profitability (29.3%), and Safety (35.4%). Growth 35% Safety 35% Profitability 29%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

88th percentile vs peers
88
Key Signals
Rev Growth YoY 32.7% 88p EPS Growth YoY 14.61 99p Revenue CAGR 3Y 23.5% 77p Asset Growth YoY 21.7% 84p
Strengths
  • Growth performance in top 20% of peers (percentile: 88)
  • Rev Growth YoY in top 20% of peers (32.7%, 88th percentile)
  • EPS Growth YoY in top 20% of peers (14.61, 99th percentile)
  • ROIC in top 20% of peers (11.1%, 88th percentile)
Risks

No significant risks identified for this axis.

Profitability

72th percentile vs peers
73
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

88th percentile vs peers
88
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Nephros, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$2.64
- - -
-39.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000